ReCode Therapeutics
Menlo Park, US · Founded 2015 · 53 employees on LinkedIn · 13 known investors
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs. The company is focused on rare genetic conditions including cystic fibrosis and primary ciliary dyskinesia.
Also known as ReCode Tx
Founders & leadership
ReCode Therapeutics was founded in 2015 by Dr. Daniel J. Siegwart.
Investors · 13
Reported raises · per SEC filings
Form D private placements$318.7M disclosed across 4 rounds · 2016–2025
▶$29.4MraisedOct 2025 · 26 investors · BiotechnologyRule 506(b)
- Rana Al-HallaqDirector
- Patricia MillicanDirector
- Shehnaaz SulimanExecutive Officer, Director
- Edward HurwitzDirector
- Alan ColowickDirector
- David LockhartExecutive Officer
- Dean MitchellDirector
- Basheer ZadaDirector
- Inai ParkDirector
- Helen S. KimDirector
- Peter A. ThompsonDirector
- Rakhshita DharDirector
- Offering amount
- $29.4M
- Amount sold
- $29.4M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$259.8MraisedSep 2023 · 28 investors · BiotechnologyRule 506(b)
- David LockhartExecutive Officer
- Alan ColowickDirector
- Helen S. KimDirector
- Oleg NodelmanDirector
- Kouki HarasakiDirector
- Rakhshita DharDirector
- Rana Al-HallaqDirector
- Shehnaaz SulimanExecutive Officer, Director, Promoter
- Trisha MillicanDirector
- Peter A. ThompsonDirector
- Edward HurwitzDirector
- Offering amount
- $290M
- Amount sold
- $259.8M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$27.5MraisedMar 2020 · 9 investors · BiotechnologyRule 506(b)
- David J LockhartExecutive Officer, Director
- Michael TorresDirector
- RA Session IIDirector
- Edward HurwitzDirector
- Helen KimDirector
- Peter ThompsonDirector
- Offering amount
- $80M
- Amount sold
- $27.5M
- Proceeds to insiders
- $400K
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$2MraisedFeb 2019 · 1 investors · Other Health CareRule 506(b)
- Arthur E JohnsonExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $2M
- First sale
- Dec 2016
- Incorporated
- Corporation, Texas, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026ReCode Therapeutics develops genetic medicines for genetically defined diseases that currently lack treatment options, with a stated initial focus on cystic fibrosis and primary ciliary dyskinesia. The company's pipeline consists of rare disease therapeutics built on optimized mRNA and gene correction approaches, and it describes its constructs as having redosing capability.
The company's core asset is its Selective Organ Targeting (SORT) lipid nanoparticle platform, a modular delivery technology intended to direct genetic payloads to organs, tissues and cells beyond the liver. ReCode also positions the platform as a partnering asset, citing the ability to package and deliver a range of genetic cargo through multiple routes of administration.
Traction
The company reports a pipeline of rare disease therapeutics based on optimized mRNA and gene correction and is actively recruiting in translational sciences, chemistry and bioanalytical development.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
ReCode presents its SORT LNP platform as the first to enable highly targeted delivery of genetic medicines to organs, tissues and cells beyond the liver, differentiating it from lipid nanoparticle delivery systems used in mRNA COVID-19 vaccines.
The company differentiates on delivery: a modular lipid nanoparticle platform engineered for selective organ and tissue targeting outside the liver, compatible with varied genetic cargo and administration routes, and supporting redosing.
Technology
ReCode's Selective Organ Targeting (SORT) lipid nanoparticle platform is described by the company as a first-in-class modular delivery technology designed to extend beyond the lipid nanoparticle systems used in mRNA COVID-19 vaccines, enabling targeted delivery of genetic medicines to organs, tissues and cells beyond the liver and supporting multiple routes of administration and a range of genetic cargo types, including mRNA and gene correction constructs with redosing capability.
Go-to-market
ReCode advances its own pipeline of rare disease genetic medicines and additionally makes its delivery platform available for partnering, citing the platform's versatility in cargo and routes of administration.
Patients with genetically defined rare diseases that have no existing treatment options, including cystic fibrosis and primary ciliary dyskinesia.
Geography
Operations and open roles are based in Menlo Park, California.
History
Vladimir Kharitonov, Ph.D., joined ReCode in 2020 as Senior Vice President of CMC and Pharmaceutical Sciences after two decades at Pacira Pharmaceuticals. The company's board includes investor representatives from Matrix Capital Management Company (Alan Colowick, M.D., M.P.H.) and Pfizer Ventures (Rana Al-Hallaq, Ph.D.).
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 2
by search overlap
Companies competing with ReCode Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 1
launches, deals, and filingsVladimir Kharitonov, Ph.D., joined ReCode Therapeutics in 2020 to lead CMC and Pharmaceutical Sciences, after roles at Pacira Pharmaceuticals from 2000 to 2020, including VP of Research and Development from 2010.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWiregeekwire.com · Jul 2026▸Research sources · 1
primary sources listed
- ReCode Therapeuticsrecodetx.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does ReCode Therapeutics do?
- Clinical-stage genetic medicines company using organ-targeting lipid nanoparticles to deliver mRNA and gene correction therapies.
- Who founded ReCode Therapeutics?
- ReCode Therapeutics was founded by Dr. Daniel J. Siegwart in 2015.
- Who are ReCode Therapeutics's investors?
- ReCode Therapeutics's investors include Aju IB Invesment Corporation, EcoR1 Capital, Evolution VC Partners, MPM BioImpact, OrbiMed, OUP (Osage University Partners), Pfizer Venture Investments, Sanofi Ventures and 5 more.
- How much funding has ReCode Therapeutics raised?
- ReCode Therapeutics has disclosed $318.7M raised across 4 rounds.
- Where is ReCode Therapeutics headquartered?
- ReCode Therapeutics is headquartered in Menlo Park, US.